Role of NADPH oxidase in cardiovascular disease

With the discovery of non-phagocytic NADPH oxidase in the vasculature and other tissues and the development of specific inhibitors, our lab has pioneered exploration of the role of NADPH oxidase in cardiovascular diseases including :


  • Systemic hypertension
  • Pulmonary hypertension
  • Atherosclerosis
  • Aging

Cifuentes ME, Rey FE, Carretero OA, Pagano PJ. Upregulation of p67phox and gp91phox in aortas from angiotensin II-infused mice. Am J Physiol Heart Circ Physiol. 2000 Nov; 279(5):H2234-40. PubMed PMID: 11045958

Jacobson GM, Dourron HM, Liu J, Carretero OA, Reddy DJ, Andrzejewski T, Pagano PJ. Novel NAD(P)H oxidase inhibitor suppresses angioplasty-induced superoxide and neointimal hyperplasia of rat carotid artery. Circ Res. 2003; 92(6):637-43. PubMed PMID: 12609967

Liu J, Yang F, Yang XP, Jankowski M, Pagano PJ. NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler Thromb Vasc Biol. 2003; 23(5):776-82. PubMed PMID: 12637340

Quesada IM, Lucero A, Amaya C, Meijles DN, Cifuentes ME, Pagano PJ, Castro C. Selective inactivation of NADPH oxidase 2 causes regression of vascularization and the size and stability of atherosclerotic plaques. Atherosclerosis. 2015, 242(2):469-75. PubMed PMID: 26298737, PMCID: PMC4818577

Sahoo S, Meijles DN, Al Ghouleh I, Tandon M, Cifuentes-Pagano E, Sembrat J, Rojas M, Goncharova E, Pagano PJ . MEF2C-MYOCD and Leiomodin1 Suppression by miRNA-214 Promotes Smooth Muscle Cell Phenotype Switching in Pulmonary Arterial Hypertension. PLoS One. 2016,11(5):e0153780. PubMed PMID: 27144530, PMCID: PMC4856285